Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
ARCH Venture Partners is a venture capital firm founded in 1986, with headquarters in Chicago, Illinois, and an additional office in Seattle, Washington. The firm has established itself as a leader in early-stage investments, particularly in the life sciences and physical sciences sectors. Over the past 30 years, ARCH has developed a reputation for its contrarian investment approach, focusing on revolutionary technologies that can significantly impact human health.
Currently, ARCH manages approximately $3 billion in assets under management (AUM) and has invested in 279 companies. The firm is recognized for its unique model of co-founding startups alongside leading scientists and researchers, which allows it to bridge the gap between academic research and commercial applications. ARCH's notable milestones include successful exits such as Grail and Illumina, showcasing its ability to identify and nurture groundbreaking innovations.
ARCH Venture Partners specializes in early-stage biotechnology investments, typically providing funding between $2 million and $20 million. The firm targets transformative technologies in sectors such as biotech, healthcare, and artificial intelligence, with a particular emphasis on infectious disease, mental health, immunology, and genomic tools. ARCH's investment strategy includes co-founding companies directly with university researchers, allowing for a hands-on approach to building successful ventures.
The firm operates primarily in North America and seeks to back companies that are developing solutions capable of preventing, detecting, and curing diseases. ARCH's commitment to supporting innovative life science companies is evident in its active investment strategy, having made 10 investments in the last 12 months.
ARCH Venture Partners has a diverse portfolio of notable companies, including:
These companies represent ARCH's commitment to investing in pioneering technologies that address significant medical challenges.
Robert Nelsen - Co-founder & Managing Director, known for his expertise in biotechnology investments.
Keith Crandell - Co-founder & Managing Director, has a strong background in life sciences.
Kristina Burow - Managing Director, specializes in early-stage investments.
Steve Gillis, Ph.D. - Managing Director, focuses on biotech and healthcare.
Paul Berns - Managing Director, brings extensive experience in venture capital.
Mark McDonnell - Managing Director, CFO & CAO, oversees financial operations.
Jason Doren - General Counsel, provides legal guidance.
Brian Cuneo - Senior Partner, involved in strategic decision-making.
Carol Suh - Partner, focuses on investment strategy.
Ari Nowacek, M.D., Ph.D. - Partner, specializes in healthcare investments.
Sean Kendall - Partner (Europe), expands ARCH's reach in European markets.
Corey Ritter - Partner, involved in portfolio management.
John Maraganore, Ph.D. - Venture Partner, has a strong background in biotech.
George Scangos, Ph.D. - Venture Partner, known for his leadership in biotech companies.
Luciana Borio, M.D. - Venture Partner, brings expertise in public health.
Joseph Jeong, Ph.D. - Venture Partner, focuses on scientific innovation.
Mary Chamberlain-Tharp, Ph.D. - Venture Partner, specializes in biotech investments.
Kevin Hrusovsky - Venture Partner, known for his work in life sciences.
Vicki Sato, Ph.D. - Venture Partner, has extensive experience in biotech.
Jonathan Lim, M.D. - Venture Partner, focuses on healthcare innovation.
Richard Heyman, Ph.D. - Venture Partner, specializes in drug development.
Jay Parrish, Ph.D. - Venture Partner, involved in scientific research.
Patrick Weiss - Venture Partner, focuses on investment strategy.
Inca Coman, Ph.D. - Venture Partner, specializes in biotech.
Jake Bauer - Venture Partner, involved in portfolio management.
Axel Bouchon, Ph.D. - Venture Partner, focuses on scientific innovation.
Olivia Zetter - Strategic Advisor & Venture Partner, provides strategic insights.
Mayu Yoshikawa, Ph.D. - Venture Partner, specializes in healthcare investments.
Nilay Thakar, Ph.D. - Principal, involved in investment analysis.
Peter Mintun, Ph.D. - Associate, supports investment teams.
Su Fu - Affiliate, provides additional support to the firm.
Startups interested in pitching to ARCH Venture Partners should use their [contact page](https://www.archventure.com/contact/) to submit inquiries. It is recommended to include a comprehensive pitch deck that outlines the business model, technology, and team background. Response times may vary, but founders should expect a thorough review process.
ARCH Strategic Partnerships (ASP) is an initiative designed to foster relationships between industry leaders and innovative labs in the physical and life sciences. ASP provides consulting services aimed at helping corporations build innovation-driven technology commercialization and business development practices globally. This program enhances ARCH's ability to connect startups with valuable resources and expertise.
On December 1, 2025, ARCH Venture Partners made its latest investment, continuing its active engagement in the biotechnology sector. In the past year, the firm has completed 10 investments, reflecting its commitment to supporting innovative life science companies. Notable recent investments include Agios Pharmaceuticals and GRAIL, underscoring ARCH's focus on addressing significant medical challenges.
Q?
What are ARCH Venture Partners' investment criteria?
ARCH focuses on early-stage biotechnology companies, particularly those developing transformative technologies in healthcare and life sciences. They typically invest between $2 million and $20 million.
Q?
How can startups apply or pitch to ARCH?
Startups can pitch to ARCH Venture Partners through their [contact page](https://www.archventure.com/contact/). It is advisable to include a detailed business plan and information about the founding team.
Q?
What makes ARCH different from other venture capital firms?
ARCH is known for its contrarian investment approach and its unique model of co-founding companies with leading scientists, which allows for a deeper involvement in the development process.
Q?
What is ARCH's geographic scope?
ARCH primarily invests in North America but operates globally, seeking innovative companies that can make a significant impact on human health.
Q?
What is ARCH's post-investment involvement like?
ARCH is deeply involved in the development of its portfolio companies, providing guidance, strategic partnerships, and industry insights to help navigate challenges.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.